| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514399000 | Chalcogen or nitrogen bonded indirectly to the imidazole ring by nonionic bonding | 89 |
| 20090143452 | Use of prochloraz for wood protection - The active compound prochloraz and fungicidal compositions based on prochloraz are highly suitable for protecting wood and timber products against attack and/or destruction by soft-rot fungi. | 06-04-2009 |
| 20110196006 | IMAZALIL COMPOSITIONS COMPRISING ALKOXYLATED AMINES - The present invention relates to the use of alkoxylated amines to enhance the activity of fungicidal formulations comprising the fungicidal compound imazalil. It also relates to formulations comprising imazalil and alkoxylated amines. These formulations are useful to protect materials, plants, fruits or seeds against fungi. | 08-11-2011 |
| 20100076043 | NITRIC OXIDE AMINO ACID ESTER COMPOUND, COMPOSITIONS FOR INCREASING NITRIC OXIDE LEVELS AND METHOD OF USE - There is provided novel amino acid ester compounds comprising at least one nitric oxide releasing group and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one amino acid ester compound comprising at least one nitric oxide releasing group, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. Also provided are compositions for increasing nitric oxide physiological levels in a subject, methods for increasing nitric oxide physiological levels in a subject, methods for improving a subject's muscle strength, athletic performances and/or lean body mass gain and or performance in a subject. | 03-25-2010 |
| 20110281923 | ANTAGONISTS OF THE MAGNESIUM BINDING DEFECT AS THERAPEUTIC AGENTS AND METHODS FOR TREATMENT OF ABNORMAL PHYSIOLOGICAL STATES - This invention provides a class of therapeutic compounds and methods for the treatment of mammals with physiological disorders, such as for example a frequently occurring type of essential hypertension, which are critically associated with the decreased binding of magnesium to the plasma membranes of their cells. These methods consist of administering to a mammal in need of such treatment a compound selected from a series of disubstituted trans, trans 1,3-butadienes, 1,3-disubstituted perhydrobutadienes, 1,2-disubstituted trans ethylenes and 1,2 disubstituted ethanes and disubstituted propanes, each of which embodies, in common, the unique structural feature essential for the biological activity of these compounds. This invention also provides for pharmaceutical formulations that employ these novel compounds. | 11-17-2011 |
| 20100222403 | Micogel Topical Formulations - The present invention encompasses anhydrous micogel formulations containing miconazole and methods of use for the treatment of topical disorders including acne. | 09-02-2010 |
| 20110071204 | PERCUTANEOUS ABSORPTION PREPARATION - This present invention provides a percutaneous absorption type pharmaceutical preparation which includes 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide as the active ingredient and a backbone for transdermal system, and satisfies at least one of the following conditions (1) and (2). The pharmaceutical preparation of the present invention enables absorption of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide, which has a low ability to be absorbed from the skin, from the skin into the body continuously and efficiently.
| 03-24-2011 |
| 20120035233 | MEDICINAL CREAM MADE USING MICONAZOLE NITRATE AND CHITOSAN AND A PROCESS TO MAKE THE SAME - The present invention is directed to a composition for treating fungal skin infections, along with skin rejuvenation. More particularly, the present invention relates to a pharmaceutical cream comprising a biopolymer, and an antifungal active ingredient. It discloses a composition for treating fungal skin infections along with skin rejuvenation containing a) a biopolymer in the form of chitosan, b) an active pharmaceutical ingredient (API) composition in the form of miconazole nitrate used in treating fungal skin infections, c) a cream base containing primary and secondary emulsifiers, waxy materials, co-solvents, acids, preservatives, buffering agents, anti oxidants, chelating agents, and humectants and d) water. The active ingredients, namely chitosan, and an anti fungal agent in the form of miconazole nitrate, are incorporated in cream base for use in treating fungal skin infections with allergy & itching, & wounds on human skin involving contacting human skin with the above identified composition. | 02-09-2012 |
| 20090286841 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS - Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed. | 11-19-2009 |
| 20090247600 | REMEDY FOR CORNEAL DISEASES - A therapeutic agent for a corneal disease comprising ozagrel or a salt thereof as an active ingredient is provided. The purpose is to find a substance capable of effectively treating/ameliorating a corneal disease which has been increased in the number of cases thereof in recent years and to provide a therapeutic agent for a corneal disease comprising the substance as an active ingredient. | 10-01-2009 |
| 20080221190 | High Purity Butoconazole Nitrate with Specified Particle Size and a Process for the Preparation Thereof - One object of the invention is high purity butoconazole nitrate of the formula (I) (I) containing maximum 0.1 wt % of chemical impurities, wherein at least 95% of the particles of the substance are below 75pm by diameter, whereas at least 99% of the particles are below 250 μm by diameter, and process for its preparation. A pharmaceutical composition comprising as active ingredient, high purity butoconazole nitrate of specified particle size in admixture with known auxiliaries is also within the scope of | 09-11-2008 |
| 20120029041 | 2-ARYL IMIDAZOLINE DERIVATIVES - 2-Aryl imidazoline derivatives are provided that are useful as anti-obesity agents or the like. A compound represented by Formula (I) or a pharmaceutically acceptable salt thereof: wherein R | 02-02-2012 |
| 20120129906 | MODULATORS OF S1P RECEPTORS - The present invention relates to novel diphenylethyne derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 05-24-2012 |
| 20120083515 | BIOADHESIVE GEL BASED ON HYDROXYETHYLCELLULOSE - Disclosed are compositions in the form of a bioadhesive gel that adheres to the mucous membranes, in particular the vaginal mucosa, for the application of active ingredients and/or principles, comprising hydroxyethylcellulose as the only gelling agent. | 04-05-2012 |
| 20080300290 | Novel Beta-Agonists, Process for Their Preparation and Their Use as Medicaments - Compounds of general formula (I) | 12-04-2008 |
| 20110039906 | ANTIBACTERIAL COMBINATION THERAPY - There is described a composition comprising a therapeutically active imidazole, or a derivative thereof, and disulfiram, or a derivative thereof, for treating an infection contributed to or caused by multi-drug resistant bacterial species. | 02-17-2011 |
| 20120101140 | Econazole Composition and Methods of Treatment Therewith - The invention provides a water-based composition for treating an infection by a dermatophyte fungus comprising econazole or a pharmaceutically acceptable salt thereof. Also provided are methods of treatment utilizing the water-based foam composition, as well as its preparation. | 04-26-2012 |
| 20120101139 | Econazole Composition and Methods of Treatment Therewith - The invention provides a water-based composition for treating an infection by a dermatophyte fungus comprising econazole or a pharmaceutically acceptable salt thereof. Also provided are methods of treatment utilizing the water-based foam composition, as well as its preparation. | 04-26-2012 |
| 20110160266 | Novel Anti-Arrhythmia Agent - It has been discovered that SKF-96365 prevents and reverses ectopic activity in myocyte cells, and that SKF-96365 is effective against all types of ectopic activity. Methods are provided using SKF-96365 and its derivatives to prevent and reverse electromechanical disorders of myocytes; these include methods of treatment and prevention of cardiac arrhythmias in human and animal subjects. These further include methods of preventing and reversing arrhythmias in cardiac muscles and hearts. These further include methods of preventing and reversing spontaneous mechanical activity in a myocyte. Pharmaceutical drugs for the treatment and prevention of cardiac arrhythmia are described, based on SKF-96365. Kits for employing the methods are also described. | 06-30-2011 |
| 514400000 | At imidazole ring carbon | 71 |
| 20110196007 | MONOCYCLIC CYANOENONES AND METHODS OF USE THEREOF - The present invention features monocyclic cyanoenone compositions and methods for using the same in the treatment of diseases such as cancer, inflammatory diseases and neurodegenerative diseases. | 08-11-2011 |
| 20130085170 | COMPOSITIONS COMPRISING AMINO ACIDS, WITH PRO-ANGIOGENIC ACTIVITY - Composition comprising leucine, isoleucine, valine threonine and lysine for treating angiogenic disorders in elderly subjects. | 04-04-2013 |
| 20100076044 | THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE AND TNF-ALPHA PRODUCTION INHIBITOR - Disclosed is an agent for use in the treatment or prevention of inflammatory bowel disease. Also disclosed is an agent for inhibiting the production of TNF-α. A therapeutic or prophylactic agent for inflammatory bowel disease comprising at least one amino acid selected from the group consisting of lysine, histidine, phenylalanine, methionine, tryptophan, glutamine, glycine, cysteine, cystine and threonine, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day; and a TNF-α production inhibitor comprising an amino acid selected from the group consisting of histidine, phenylalanine and tryptophan, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day. | 03-25-2010 |
| 20130035362 | Stable Anti-inflammatory Solutions for Injection - The present invention relates to stable liquid formulations of ketoprofen, amitriptyline, and oxymetazoline. | 02-07-2013 |
| 20130041006 | PHARMACEUTICAL COMPOSITION FOR INTRACELLAR ACIDIFICATION WITH CIS-UROCANIC ACID - A pharmaceutically acceptable agent able to acidify the cell cytoplasm for the manufacture of a pharmaceutical composition useful for causing immunosuppression in a person or animal, where an effective amount of the agent is administered in an essentially non-dissociated form to the person or animal, and where the agent is admixed with a carrier to adjust the pH of the composition to the pH range 6.1 to 7.0. A pharmaceutical composition is also disclosed. | 02-14-2013 |
| 20100099727 | Amino acid and peptide conjugates of arylalkylic acids for cosmetic use - The invention provides novel compounds of general formula I | 04-22-2010 |
| 20100069453 | Certain Chemical Entities, Compositions, and Methods - Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed. | 03-18-2010 |
| 20090326031 | ANTIVIRAL USE OF CATIONIC SURFACTANT - Cationic surfactants derived from the condensation of fatty acids and esterified dibasic amino acids, such as from lauric acid and arginine, in particular the ethyl ester of the lauramide of the arginine monohydrochloride (LAE), may be used for the protection against the growth of the microorganisms. The cationic surfactants of this type are also effective against virus infections. Addition of LAE to cultures of Herpes virus type 1 Vaccinia virus and bovine parainfluenzae 3 virus leads to nearly complete reduction of the virus organisms in these cultures, such effects being observed after 5 and 60 minutes. | 12-31-2009 |
| 20090306165 | DIPEPTIDE COMPOUNDS CONTAINING D-HISTIDINE - D-Camosine lipophilic derivatives are disclosed, characterized by higher bioavailability than L-camosine and intended for the pulmonary distribution where they can exert detoxifying activity on the cytotoxic carbonyl compounds induced by cigarette smoke. | 12-10-2009 |
| 20090012142 | Compositions and Methods for Increasing Lean Muscle Mass and/or Reducing Fat Gain - Compositions and methods for increasing lean muscle mass and/or reducing fat gain in growing animals by feeding the animals a composition having a total lysine to metabolizable energy ratio of from about 2.5 to about 6 g/Mcal and comprising (a) arginine in a total arginine to total lysine ratio of from about 1.1 to about 1.6; (b) isoleucine in a total isoleucine to total lysine ratio of from about 0.8 to about 1.3; (c) leucine in a total leucine to total lysine ratio of from about 1.8 to about 3.0; (d) valine in a total valine to total lysine ratio of from about 0.8 to about 1.4; and (e) methionine and cystine in a total methionine plus cystine to total lysine ratio of from about 0.8 to about 1.7. | 01-08-2009 |
| 20090012141 | Composition and Method for Making Oligo-Benzamide Compounds - The present invention includes compound compositions and methods of making compounds that include an oligo-benzamide compound having at least two optionally substituted benzamides. | 01-08-2009 |
| 20130123319 | Medthod of Treating a systemic inflammatory disorder and damaged internal tissues - 3% Glycerin plus 3% amino acids intravenously used for nutritional purposes produces a rapid remission of an acute exacerbation in Behcet's Disease. External manifestations such as oral, vulva, penile and skin lesions rapidly heal when Glycerin is added to the amino acids. While the disease process in Behcet's Disease is likely improved by amino acids alone, the robustness of the healing of open lesions and the overall well-being of the patient in acute exacerbations is greatly enhanced by the addition of 3% Glycerin to the IV fluid. IV 3% Glycerin and 3% Amino Acids also produced remissions in Myasthenia Gravis, Guillain-Barre Disease, and Chronic Inflammatory Demyelinating Polyneuropathy. 3% Glycerin with amino acids could cause healing in many autoimmune diseases and can help external and internal lesions to heal. | 05-16-2013 |
| 20110294862 | TREATMENT OR PREVENTION OF HYPOTENSION AND SHOCK - A method for the prevention and treatment of hypotension and shock due to low peripheral resistance, comprising administering to a mammal in need thereof an effective amount of a certain imidazole derivative or pharmaceutically acceptable ester or salt thereof, and a method for the treatment of cardiopulmonary resuscitation, comprising administering to a mammal in need thereof an effective amount of a certain imidazole derivative or pharmaceutically acceptable ester or salt thereof. | 12-01-2011 |
| 20090023794 | Use of Sumoylation Inhibitors for the Treatment of Neurodegenerative Disease - The invention generally provides screening methods for the identification of therapeutic compounds useful for the treatment of a neurodegenerative disease, and related prophylactic and therapeutic compositions and methods. | 01-22-2009 |
| 20080275100 | PROPOFOL ANALOGS, PROCESS FOR THEIR PREPARATION, AND METHODS OF USE - The invention provides para substituted dialkylphenol derivatives of propofol. The invention further provides pharmaceutical compositions comprising such analogs, methods for preparing such analogs, and methods of using such analogs to induce general anesthesia, sedation, and/or hypnotic or sleep effects in a patient. | 11-06-2008 |
| 20110275685 | SALT AND POLYMORPHS OF A KINESIN INHIBITOR COMPOUND - The present invention relates to salts, polymorphs and hydrates of the kinesin inhibitor compound N-((S)-3-amino-4-fluorobutyl)-N-((R)-1-(1-benzlyl-4-(2,5-difluorophenyl)-1H-imidazol-2-yl)-2,2-dimethylpropyl)-2-hydroxyacetamide, processes to prepare such salts, polymorphs and hydrates and a liquid formulation comprising at least one of these salts, polymorphs and hydrates. | 11-10-2011 |
| 20110301214 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL - Disclosed herein is a pharmaceutical composition comprising (3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl)methanol and methods of using the composition to treat chronic pain. | 12-08-2011 |
| 20090137654 | METHODS OF MODULATING BINDING OF SON OF SEVENLESS TO PHOSPHATIDIC ACID AND IDENTIFYING COMPOUNDS THAT MODULATE SUCH BINDING - The present invention relates to methods of modulating binding of Son of sevenless to phosphatidic acid and identifying compounds that modulate such binding. In particular, the present invention relates to a method of controlling pleckstrin homology domain-dependent membrane recruitment of Son of sevenless or histone folds domain-dependent membrane recruitment of Son of sevenless. Also disclosed are methods of controlling Ras and treating a subject for a condition mediated by Ras. The present invention also relates to a method of identifying compounds potentially effective in treating a condition mediated by Ras. | 05-28-2009 |
| 20080234345 | METHOD FOR REDUCING OR ALLEVIATING INFLAMMATION IN THE DIGESTIVE TRACT - A method is provided for reducing or alleviating inflammation or a pathological process associated therewith or secondary thereto in a subject having an inflammatory disease of the digestive tract. The method comprises administering to the subject an anti-inflammatorily effective amount of an ACE2 inhibitor. | 09-25-2008 |
| 20120129907 | HISTIDINOL DEHYDROGENASE INHIBITORS, AND USE THEREOF AS MEDICAMENTS - Compounds of general formula (I) below: | 05-24-2012 |
| 20100069454 | Novel compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection - The present invention provides compounds, pharmaceutical compositions and methods for treating, immuno-allergical diseases, autoimmune diseases, and organ or tissue rejection following transplantation. | 03-18-2010 |
| 20090286842 | NAPHTHYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS - Disclosed herein is a method of treating stress urinary incontinence comprising administering a compound to a mammal in need thereof, wherein said compound has the formula | 11-19-2009 |
| 20080275099 | Solid Forms of (E)-1-(4-((1R,2S,3R)-1,2,3,4-Tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone Oxime - Solid forms of (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime, compositions comprising them, and methods of their use are disclosed. | 11-06-2008 |
| 20100137393 | PREDICTION AND PROPHYLACTIC TREATMENT OF TYPE 1 DIABETES - An in vitro method for predicting the onset of type 1 diabetes (T1 D) in a subject, comprises the steps of: (a) measuring the concentration of at least one amino acid, amino acid derivative or amino acid metabolite in a biological sample taken from the subject; (b) determining the subject's HLA genotype; (c) assigning the subject's genetic risk of developing T1 D on the basis of the subject's HLA genotype; (d) combining the information obtained in step (a) with the information in step (c); and (e) predicting the likelihood of onset of T1 D based upon the combination of step (d). The diagnostic method can be used to select target subjects for T1 D prophylactic treatment, and as part of a T1 D preventative treatment regime for neonates having a likelihood of developing childhood T1 D. | 06-03-2010 |
| 20090186930 | NOVEL IMIDAZOLE DERIVATIVES, PREPARATION AND USER THEREOF AS MEDICINE - The invention concerns novel imidazole derivatives of general formula (I), wherein Z′ and Z represent different variable groups. Said products have an antitumoral activity. The invention also concerns pharmaceutical compositions containing said products and their use for preparing antitumoral medicine. | 07-23-2009 |
| 20090105324 | IMIDAZOLE DERIVATIVES FOR USE AS EDG-1 ANTAGONISTS - The invention relates to chemical compounds of formula (I): or pharmaceutically acceptable salts thereof, which possess Edg-1 antagonistic activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man. | 04-23-2009 |
| 20080262066 | Azole Derivatives as Cannabinoid CB1 Receptor Antagonists - A novel azole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB | 10-23-2008 |
| 20110144175 | METHOD FOR CONTROLLING DEGRADATION OF AGRICULTURAL CHEMICAL ACTIVE INGREDIENT - When Cyazofamid is formulated in accordance with a conventional formulation method, Cyazofamid is degraded in some cases. The problem to be solved by the present invention is to improve storage stability of the formulation by controlling degradation of Cyazofamid as an agricultural chemical active ingredient. The present invention provides a method for controlling degradation of an agricultural chemical active ingredient, Cyazofamid, which comprises using at least one stabilizer selected from the group consisting of epoxidized animal oil and/or vegetable oil, a nonionic surface active agent of polyoxyethylene, an anionic surface active agent of polyoxyethylene, polyhydric alcohol and a basic substance. | 06-16-2011 |
| 20090247601 | PEPTIDE DERIVATIVES WITH THERAPEUTIC ACTIVITY - Dipeptide compounds containing a histidine residue proved to have interesting blocking activity on secondary products from lipid oxidative stress, in particular on unsaturated aldehydes such as malondialdehyde and hydroxynonenal, which are known to contribute to the inset of quite a number of chronic pathologies such as neurodegenerative, inflammatory chronic, cardiovascular diseases, diabetes complications and cataract. | 10-01-2009 |
| 20090239922 | Kinesin inhibitors as cancer therapeutics - The invention provides novel compounds having a substituted imidazole ring, and methods of using such compounds for the treatment of certain disorders such as hematological cancers and solid tumors. The compounds of the invention are tri-substituted imidazole derivatives that inhibit KSP. These compounds are also useful for the treatment of drug resistant tumors, such as solid tumors that express elevated levels of P-glycoprotein. | 09-24-2009 |
| 20100197751 | COMPOSITIONS OF PEGYLATED SOLUBLE TUMOR NECROSIS FACTOR RECEPTORS AND METHODS OF PREPARING - The present invention provides for improved compositions comprising a PEGsTNF-R1 which, in addition to having useful higher concentrations, demonstrate decreased viscosity (<400 cP) and improved stability. | 08-05-2010 |
| 20090298901 | (E)-1-(4-((1R,2S,3R)-1,2,3,4-TETRAHYDROXYBUTYL)-1H-IMIDAZOL-2-YL)ETHANONE OXIME DIHYDRATE AND METHODS OF ITS USE - (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)-ethanone oxime dihydrate, compositions comprising it, and methods of its use are disclosed. | 12-03-2009 |
| 20090076111 | Methods for improving glycemic control in humans - The present invention is directed to methods for improving glycemic control in humans and animals comprising the step of administering a composition comprising an amino acid content including 4-hydroxyisoleucine in an amount between about 60% and about 70% of a total weight of the amino acid content, together with one or more amino acids selected from the group consisting of glutamate, aspartate, arginine, cysteine, threonine, serine, glycine, alanine, valine, methionine, isoleucine, and histidine (inclusive of any chemical salts, anhydrides, or isomers of any of the foregoing), in addition to, alkaloids, glycosides, volatile oils, saponins, sapogenins, mannans, flavonoids, fatty acids, vitamins and provitamins, minerals, and carbohydrates. Fasting blood glucose and glucose tolerance were studied in normal human subjects, in human subjects diagnosed with Metabolic Syndrome X, and in diabetic rats by means of dosing the subjects with compositions comprising 4-hydroxyisoleucine in an amount between about 20% and about 30% of the total weight of the composition, wherein improving glycemic control in standard glucose tolerance tests. | 03-19-2009 |
| 20100144816 | FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS - In its many embodiments, the present invention provides a novel class of naphthene- and indane-type as inhibitors of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions. | 06-10-2010 |
| 20090076110 | Amino Acid Compounds - An Amino Acid Compound is described. The Amino Acid Compound may comprise an Amino Acid and one of a Nitrate and a Nitrite. The Amino Acid may be one of Agmatine, Arginine, Beta Alanine, Citrulline, Creatine, Glutamine, L-Histidine, Isoleucine, Leucine, Norvaline, Ornithine, and Valine. | 03-19-2009 |
| 20120142746 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR LOWERING INTRAOCULAR PRESSURE - The present invention relates to method of lowering intraocular pressure in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising a ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl]methanol, of enantiomers thereof, of tautomers thereof, pharmaceutical compositions containing them and their use as pharmaceuticals. | 06-07-2012 |
| 20100331383 | COMPOUNDS FOR THE TREATMENT OF AIDS AND OTHER VIRAL DISEASES - The present invention provides methods for treating Acquired Immunodeficiency Syndrome (AIDS) and other viral diseases and Human Immunodeficiency Virus (HIV) related infections by administering one or more compounds of formula I: | 12-30-2010 |
| 20110245312 | AMINO ACID BASED COMPOSITIONS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS DISTINGUISHED BY INSUFFICIENT MITOCHONDRIAL FUNCTION - The present invention relates to compositions suitable for the treatment of pathological conditions distinguished by insufficient or reduced mitochondrial function. The compositions comprise, as principal active ingredients, the amino acids leucine, isoleucine and valine. The compositions may also comprise, as further active ingredients, amino acids threonine and lysine, and optionally, histidine, phenylalanine, methionine, tryptophan, as well as tyrosine and cysteine. | 10-06-2011 |
| 20110245311 | Histidine Derivatives - Disclosed herein are the compositions and methods for a compound of Formula Ia or Ib. | 10-06-2011 |
| 20110124697 | COMPOSITIONS BASED ON AMINOACIDS, SUITABLE FOR THE TREATMENT OF HEART FAILURE - Compositions based on amino acids are described, in particular for oral or parenteral use, suitable for treating heart insufficiency. The compositions according to the invention comprise up to 75% of the branched chain amino acids leucine, isoleucine and valine, as active ingredients. Preferably, the compositions also comprise, as further active ingredients, up to 50% of theronine and lysine. Other essential amino acids are preferably also provided (in particular methionine, phenylalanine, histidine, triphtophan) as well as non essential amino acids (in particular tyrosine and/or cyst(e)ine—i.e., cystine and cyst(e)ine). Other amino acids can be added, provided that their sum is in a percentage being lower than 20% with respect to the other active ingredients, and less than 10% for each single amino acid. | 05-26-2011 |
| 20110245313 | AMINO ACID BASED COMPOSITIONS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS DISTINGUISHED BY INSUFFICIENT MITOCHONDRIAL FUNCTION - The present invention relates to compositions suitable for the treatment of pathological conditions distinguished by insufficient or reduced mitochondrial function. The compositions comprise, as principal active ingredients, the amino acids leucine, isoleucine and valine. The compositions may also comprise, as further active ingredients, amino acids threonine and lysine, and optionally, histidine, phenylalanine, methionine, tryptophan, as well as tyrosine and cysteine. | 10-06-2011 |
| 20120035234 | COMPOSITION COMPRISING FREE AMINO ACIDS - A composition is described that can be used in prevention or treatment of patients having impaired gastro-intestinal tract function. The composition comprises free amino acids including about 9.0% to about 17.0% glutamic acid. Methods of treatment of impaired gastro-intestinal tract function are described. | 02-09-2012 |
| 20120149746 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR TREATING RETINAL DISEASES - The present invention relates to method of treating retinal diseases in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising a ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl]methanol, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals. | 06-14-2012 |
| 20110053998 | ETOMIDATE ANALOGUES WITH IMPROVED PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES - The invention is directed to compounds according to formula (I): where R | 03-03-2011 |
| 20100267794 | ANTI-FATIGUE AGENT COMPRISING AMINO ACID COMPOSITION - Conventional amino acid compositions are primarily intended to improve athletic performance or to promote fat-burning. Provided is an anti-fatigue agent which can prevent both of muscle fatigue and nerve strain concurrently. An anti-fatigue agent which comprises an amino acid composition composed of specific amino acids in specified amounts can prevent both of muscle fatigue and nerve strain concurrently. As for the types and the ratio of the amounts of the amino acids contained in the amino acid composition, the amino acid composition preferably contains 30 to 200 parts by weight of proline, 60 to 140 parts by weight of glycine, 50 to 260 parts by weight of alanine, 50 to 130 parts by weight of lysine, 30 to 75 parts by weight of tryptophan and 20 to 40 parts by weight of histidine, more preferably further comprises 3 to 75 parts by weight of tyrosine and 15 to 45 parts by weight of arginine, still more preferably further contains 30 to 55 parts by weight of valine, 35 to 60 parts by weight of leucine and 25 to 60 parts by weight of isoleucine. | 10-21-2010 |
| 20110118325 | REL INHIBITORS AND METHODS OF USE THEREOF - This invention provides REL inhibitors which interfere with the DNA binding capacity of a REL protein. Additionally this invention provides methods of treating, abrogating, or preventing diseases which respond with a positive clinical score to a REL inhibitor. Methods of identifying REL inhibitor based on a REL protein three dimensional model are described. | 05-19-2011 |
| 20110257236 | SOLID SOLUTION OF VALINE, ISOLEUCINE, LEUCINE AND ITS MANUFACTURING METHOD - [Problem] A valine, isoleucine, leucine mixture which is excellent in the reduction of bitter taste and improved dissolution speed is provided. | 10-20-2011 |
| 20090176853 | Adamantane derivatives - The invention provides adamantane derivatives of formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy. In formula (I) D represents CH | 07-09-2009 |
| 20110313012 | Amino Acid Compounds - A method for increasing the vasodilative characteristics of amino acids in a human or animal is disclosed. The method includes administering to the human or animal a pharmaceutically effective amount of an amino acid compound consisting essentially of a nitrate or nitrite of an amino acid selected from the group consisting of Arginine, Agmatine, Beta Alanine, Citrulline, Creatine, Glutamine, L-Histidine, Isoleucine, Leucine, Norvaline, Ornithine, and Valine. | 12-22-2011 |
| 20110313011 | Amino Acid Compounds - A method for increasing the bioabsorption of amino acids in a human or animal is disclosed. The method includes administering to the human or animal a pharmaceutically effective amount of an amino acid compound consisting essentially of a nitrate or nitrite of an amino acid selected from the group consisting of Arginine, Agmatine, Beta Alanine, Citrulline, Creatine, Glutamine, L-Histidine, Isoleucine, Leucine, Norvaline, Ornithine, and Valine. | 12-22-2011 |
| 20100197752 | UROCANIC ACID DERIVATIVES USEFUL FOR THE TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES - The invention relates to derivatives of urocanic acid that have improved efficacy and/or tissue penetration properties. The invention further provides use of these derivatives in a medicament for modulating an immune-related disease in an individual. Imidazole derivative, or a salt thereof, selected from O I1 W—C—R1 H— (formula 1); o I1 W—C—R1 and HN N r<1 NH (formula 2); O O Ov ̂ W—C—R1 and HN N (formula 3); | 08-05-2010 |
| 20100305179 | ORAL SUSTAINED-RELEASE TABLET - (Object) An oral sustained-release tablet is provided, which does not cause initial rapid increases in the bloodlevels of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide (KRP-197) and can maintain constant the blood levels. | 12-02-2010 |
| 20100144815 | AMINO ACID COMPOSITION - An amino acid composition is provided that can promote fat burning, improve endurance, and reduce fatigue during, for example, marathons, and that can lessen obesity and increase stress resistance. | 06-10-2010 |
| 20090018179 | NOVEL CRYSTALS AND PROCESS OF MAKING 5-(-METHYL)-2-METHOXY-BENZOIC ACID - The present invention relates to a novel crystals of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid and methods of making the zwitterion of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid. | 01-15-2009 |
| 20120071534 | LXR MODULATORS - Compounds, pharmaceutically acceptable salts, isomers, or prodrugs thereof, of the invention are disclosed, which are useful as modulators of the activity of liver X receptors (LXR). Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed. | 03-22-2012 |
| 20110105578 | Substituted Imidazole Derivatives And Methods Of Use Thereof - The present invention provides imidazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof. | 05-05-2011 |
| 20120316212 | AMINO ALCOHOL DERIVATIVES AND THEIR THERAPEUTIC ACTIVITIES - The present invention relates to amino alcohol derivatives of general formula I: | 12-13-2012 |
| 20120122945 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL - The present invention relates to novel compounds, ester pro-drugs of [3-(1-1H-imidazol-4-yl)ethyl)-2-methylphenyl]methanol, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals in the treatment of conditions mediated by adrenergic receptors. | 05-17-2012 |
| 20080319040 | N-Acylic Aminoacid Derivatives, Method For The Production Thereof, Pharmacological Composition And The Use In The Form Anti-Allergic, Anti-Inflammatory And Hypolipidemic Agents - The present invention relates to N-acyl derivatives of amino acids and pharmaceutically acceptable salts thereof | 12-25-2008 |
| 20120129908 | Agent For The Prophylaxis And Treatment Of Highly Pathogenic Infectious Diseases - The invention relates to an agent for the treatment and/or prophylaxis of highly pathogenic infectious diseases, such as highly pathogenic influenza A (in particular, subtypes H5 and H7) and severe acute respirator syndrome caused by the genotype IV coronavirus. The agent is in the form of glutaryl histamine or a pharmaceutically acceptable salt thereof. The invention also relates to a pharmaceutical composition based on glutaryl histamine or a pharmaceutically acceptable salt thereof and to a method for the treatment and/or prophylaxis of highly pathogenic infectious diseases. | 05-24-2012 |
| 20120136036 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR TREATING SKIN DISEASES AND CONDITIONS - The present invention relates to method for treating skin diseases and skin conditions in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl]methanol, or enantiomers thereof, pharmaceutical compositions containing them and their use as pharmaceuticals. | 05-31-2012 |
| 20080255219 | RUMEN PROTECTED ESSENTIAL AMINO ACIDS - Use of essential amino acid imines and compositions containing them as a source of rumen protected essential amino acids for ruminant animals. Preferred are histidine and methionine. | 10-16-2008 |
| 20120220641 | LASER ENHANCED AMINO ACID BLEND AND USE OF SAME TO REGENERATE ACTIVE MYOCARDIAL TISSUE - The invention provides a blend of amino acid powders that have been exposed to pulsed laser radiation. The pulsed laser radiation is obtained by passing laser radiation through a device, which has a first diffraction grating, a second diffraction grating, and a refractive element positioned between the first and second diffraction gratings. Passing the laser radiation through the device cancels a portion of the laser radiation by destructive interference, and produces pulses of laser radiation by constructive interference. The blend of laser treated amino acids has been found useful in regenerating active myocardial tissue. The invention further provides a process for preparing the laser treated blend of amino acid powders and a method of regenerating active myocardial tissue with the blend. | 08-30-2012 |
| 20120083516 | Nasal sinus spray for treatment of sinus headache and method of using same - Disclosed is a nasal spray containing the combination of a vasoconstrictor and a topical local anesthetic. | 04-05-2012 |
| 20120232120 | AMINO ACID AMIDES OF PHENOXYBUTYRIC ACID DERIVATIVES - A compound of the formula: | 09-13-2012 |
| 20120270917 | ADAMANTANE ANALOGS - Provided are compounds that are capable of modulating the activity of the influenza A virus via interaction with the M2 transmembrane protein. Also provided are methods for treating an influenza A-affected disease state or infection comprising administering a composition comprising one or more compounds that have been identified as being capable of interaction with the M2 protein. | 10-25-2012 |
| 20120329846 | THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE AND TNF-ALPHA PRODUCTION INHIBITOR - Disclosed is an agent for use in the treatment or prevention of inflammatory bowel disease. Also disclosed is an agent for inhibiting the production of TNF-α. A therapeutic or prophylactic agent for inflammatory bowel disease comprising at least one amino acid selected from the group consisting of lysine, histidine, phenylalanine, methionine, tryptophan, glutamine, glycine, cysteine, cystine and threonine, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day; and a TNF-α production inhibitor comprising an amino acid selected from the group consisting of histidine, phenylalanine and tryptophan, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day. | 12-27-2012 |
| 20110319461 | NOVEL SALTS, POLYMORPHS, AND SYNTHETIC PROCESSES REGARDING IMIDAZOLE DERIVATIVE - The present invention relates to a process for producing 2-[1-(S)-carboxy-2(S)-[3-(3,5-dichloro-benzyl)-3H-imidazol-4-yl]-ethylamino]-4-methyl-pentanoic acid, as well as novel salts, including hydrates and solvates thereof, and novel crystalline and amorphous forms thereof. | 12-29-2011 |
| 20130012560 | KINESIN INHIBITORS AS CANCER THERAPEUTICS - The invention provides novel compounds having a substituted imidazole ring, and methods of using such compounds for the treatment of certain disorders such as hematological cancers and solid tumors. The compounds of the invention are tri-substituted imidazole derivatives that inhibit KSP. These compounds are also useful for the treatment of drug resistant tumors, such as solid tumors that express elevated levels of P-glycoprotein. | 01-10-2013 |
| 20120149747 | PHARMACEUTICAL COMPOSITIONS COMPRISING (3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL)METHANOL - The present invention relates to method of lowering intraocular pressure in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl]methanol, or enantiomers thereof, or tautomers thereof, pharmaceutical compositions containing them and their use as pharmaceuticals. | 06-14-2012 |
| 20130018080 | COMPOSITIONS COMPRISING AMINO ACIDS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASEAANM Dioguardi; Francesco SaverioAACI MilanoAACO ITAAGP Dioguardi; Francesco Saverio Milano ITAANM Mella; Isabella ArborioAACI MilanoAACO ITAAGP Mella; Isabella Arborio Milano ITAANM Conti; Edoardo Carlo MariaAACI MilanoAACO ITAAGP Conti; Edoardo Carlo Maria Milano ITAANM Conti; Giovanni Federico MariaAACI MilanoAACO ITAAGP Conti; Giovanni Federico Maria Milano IT - A composition comprising leucine, isoleucine, valine, threonine and lysine for treating chronic obstructive pulmonary disease. | 01-17-2013 |
